Objective: i. To identify CSF protein biomarker/s in Parkinson’s disease (PD) with cognitive impairment using LC-MS/MS proteomics. ii. To estimate the level of known AD biomarkers in CSF of PD with cognitive impairment using Enzyme Linked Immunosorbent Assay (ELISA)

Background: Cognitive impairment is a major non-motor symptom of PD. The cognitive phenotypes of PD include (a) PD with dementia (PDD) and (b) PD with mild cognitive impairment (PD-MCI). In PDD, impairments in executive and visuospatial functions predominate; alongside attention, learning and memory deficits. No biomarkers have thus far been identified for an early diagnosis of PD with cognitive impairment.

Method: Study groups:Controls, n=4; PD, n=3; PDD, n=4; Normal Pressure hydrocephalus (NPH) n=4. 1. Q-TOF-LC-MS/MS unbiased label free mass spectrometry based-proteomics was performed on CSF of subjects, who underwent neuropsychological and neuro-radiological assessments. 2. Enzyme Linked Immunosorbent Assay (ELISA) based estimation of Amyloid β-42 was also performed on CSF.

Results: The MOCA and NIMHANS neuropsychology battery scores confirmed significant decline in executive, visuo-spatial, attention and memory in the patients with PDD. The label-free quantitation (LFQ) intensity values on LC-MS/MS showed lower levels of Amyloid β A4 or Amyloid β precursor protein in PD and PDD compared to controls. A matching reduction was observed in Amyloid-β42 levels by ELISA. We are currently analysing additional CSF samples.

Conclusion: The leads obtained from the present study suggest a possibility of involvement of Amyloid-β related proteins in cognitive impairment in PD.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/identification-of-protein-biomarker-s-in-csf-of-parkinsons-disease-pd-with-cognitive-impairment/